A Phase 1 interventional study of NNC0194-0499 and Placebo in Metabolism and Nutrition Disorder and Obesity, sponsored by Novo Nordisk A/S. Completed at 1 site in United States. Open to participants aged 22 Years to 55 Years. Per ClinicalTrials.gov, last updated 2019-06-26.
Sponsored by Novo Nordisk A/S · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 207 studies in Obesity by Novo Nordisk A/S — 48 open to participants now, 66 under way, 26 of them phase 3. Obesity · Novo Nordisk A/S.
Among the 207 studies in Obesity by Novo Nordisk A/S, this one is the 128th largest by enrollment of the 166 interventional ones that give a count, is one of 14 that started in 2018, is one of 85 in phase 1, and was the 35th registered.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
Browse Obesity studies →48 of the 207 studies in Obesity by Novo Nordisk A/S are open now, in 12 countries. Recruiting first, the newest first:
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in United States
Ages 18+
Novo Nordisk A/S · Sites in Germany
Ages 18+
Novo Nordisk A/S · Sites in Japan
Ages 18+
By country, each count listing its studies:
Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.
This study: 22 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
207 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 86 · Phase 2 14 · Phase 3 62 · Phase 4 4
First in 2007; this study’s year is marked. 14 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 57 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Median enrollment 138 across the 166 interventional studies, 1,260 across the 41 observational. Of the 138 that completed or were terminated, 39 (28%) have results posted.
This tab as a report to print or save as PDF → With an account.
Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
26 of the studies in Obesity by Novo Nordisk A/S that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07011667Phase 3Novo Nordisk A/SA Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term | 2027-03-01 |
| NCT07220642Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide | 2027-05-11 |
| NCT07220759Phase 3Novo Nordisk A/SWeight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide | 2027-05-12 |
| NCT07745504Phase 3Novo Nordisk A/SA Research Study to Compare Two Different Versions of Injectable Cagrilintide and Placebo in People With Excess Body Weight | 2027-05-18 |
| NCT07225816Novo Nordisk A/SExamination of How the Duration of Fasting and Temporary Stopping of GLP-1 Medications Affect the Amount of Food Left in the Stomach in People Using Liraglutide (Injected), Semaglutide (Taken by Mouth) or Semaglutide (Injected) | 2026-12-13 |
Add all 26 to your calendar (.ics) → With an account.
Among the 207 studies in Obesity by Novo Nordisk A/S, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This study looks at a new study medicine for weight control in people with overweight or obesity. The aim of this study is to see if the study medicine is safe for people to take. The study also looks at how fast the body removes the study medicine. The participants will either get NNC0194-0499 (the study medicine) or placebo (a formula that looks like the medicine but does not have active ingredients). Which treatment the participants get is decided by chance. The participants will get 1 or more injections into the skin of stomach area once each week for 12 weeks. The study will last for about 4 to 5 months. The participants will have 18 visits to the clinic.
11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.
This study's enrollment of 57 is below the median of 67 across 9,016 interventional studies indexed under Obesity.
Browse Obesity studies →Novo Nordisk A/S is the lead sponsor of 1,408 studies on the registry; 105 are open to participants now.
Of its 205 completed or terminated interventional studies of FDA-regulated products, 101 (49%) have results posted.
Compared within Obesity, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Nutrition Disorders. The counts are of registry records indexed under each term, refreshed daily. How we classify →
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants will receive increasing doses of NNC0194-0499. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
Drug: NNC0194-0499
Participants will receive NNC0194-0499 matched placebo. The treatment period from first treatment (Day 1) to end of the treatment (Day 85) will be 12 weeks.
Drug: Placebo
Participants will receive NNC0194-0499 (s.c., in a lifted fold of the abdominal skin) injection once weekly at increasing doses of 3.0 mg, 9.0 mg, 27 mg, 60 mg, or 120 mg. Each participant will only be given one dose level. Dose escalation will proceed to the next planned dose level if there are no safety concerns raised by the investigator or by the trial safety group.
Participants will receive once weekly injections of NNC0194-0499 matched placebo.
Number of treatment emergent adverse events (TEAEs)
count of events
Time frame: From first administration of NNC0194-0499 (Day 1) to follow-up (Day 112)
Change in heart rate
measured in beats per minute
Time frame: Baseline (Day 1), Follow-up (Day 112)
Change in biochemistry
Parameters: Calcium (total), Chloride, Magnesium, Phosphate (inorganic), Potassium, Sodium, Urea (blood urea nitrogen, BUN), Uric acid, Alanine aminotransferase (ALT), Alkaline phosphatase (ALP), Amylase, Aspartate aminotransferase (AST), Creatinine kinase (CK, total), Gamma glutamyltransferase (GGT), Lactase dehydrogenase, Lipase, Albumin, Bicarbonate, Bilirubin (total), Creatinine, High sensitivity C-reactive protein (hsCRP) and Total protein in SI units
Time frame: Baseline (Day -1), Follow-up (Day 112)
Change in haematology
Parameters: Erythrocytes, Reticulocytes, Thrombocytes, Leucocytes (total), Neutrophils, Lymphocytes, Monocytes, Eosinophils, Basophils, Haemoglobin, Haematocrit, Mean corpuscular volume (MCV) and Mean corpuscular haemoglobin concentration (MCHC) in SI units
Time frame: Baseline (Day -1), Follow-up (Day 112)
Change in fibrinogen
measured in g/L
Time frame: Baseline (Day -1), Follow-up (Day 112)
Change in prothrombin time read as international normalised ratio (INR)
Time frame: Baseline (Day -1), Follow-up (Day 112)
Change in activated partial thromboplastin time (APTT)
measured in seconds
Time frame: Baseline (Day -1), Follow-up (Day 112)
Changes in electrocardiogram (ECG)
Parameters: RR interval, PR interval, QRS interval, QT interval and QTcF interval in SI units
Time frame: Baseline (Day 1), Follow-up (Day 112)
Number of injection site reactions
count of injection site reactions
Time frame: From baseline (Day 1) to follow-up (Day 112)
Occurrence of anti-NNC0194-0499 antibodies
Time frame: From baseline (Day 1) to follow-up (Day 112)
t½,SS: the terminal serum half-life of NNC0194-0499 at steady state
Calculated based on serum concentrations of NNC0194-0499
Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)
Cmax,SS: the maximum concentration of NNC0194-0499 in serum at steady state
Calculated based on serum concentrations of NNC0194-0499
Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)
tmax,SS: the time to maximum concentration of NNC0194-0499 in serum at steady state
Calculated based on serum concentrations of NNC0194-0499
Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)
CL/F SS: the apparent total serum clearance of NNC0194-0499 at steady state
Calculated based on serum concentrations of NNC0194-0499
Time frame: From last dose (Day 78, pre-dose) until the follow-up (Day 112)
Change in systolic blood pressure
measured in mmHg
Time frame: Baseline (Day 1), Follow-up (Day 112)
Change in diastolic blood pressure
measured in mmHg
Time frame: Baseline (Day 1), Follow-up (Day 112)
Plan to share: Yes — According to the Novo Nordisk disclosure commitment on novonordisk-trials.com
Data sharing details ↗ · www.novonordisk-trials.com
No publications or documents are linked to this record.
Ran from Mar 2018 to primary completion in Jun 2019, 14 months.
Of 334 industry-sponsored phase 1 interventional studies under Obesity, half reached primary completion within 9 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 15. This study's 14 months is above that.
Counting every sponsor, half of 439 studies reached it within 11 months; a quarter within 6 and three quarters within 24.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jun 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Zalfermin